NO2501406T3 - - Google Patents

Info

Publication number
NO2501406T3
NO2501406T3 NO10831896A NO10831896A NO2501406T3 NO 2501406 T3 NO2501406 T3 NO 2501406T3 NO 10831896 A NO10831896 A NO 10831896A NO 10831896 A NO10831896 A NO 10831896A NO 2501406 T3 NO2501406 T3 NO 2501406T3
Authority
NO
Norway
Application number
NO10831896A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2501406T3 publication Critical patent/NO2501406T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0283Shigella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO10831896A 2009-11-19 2010-11-16 NO2501406T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27293109P 2009-11-19 2009-11-19
PCT/US2010/002980 WO2011062615A1 (en) 2009-11-19 2010-11-16 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells

Publications (1)

Publication Number Publication Date
NO2501406T3 true NO2501406T3 (de) 2018-05-19

Family

ID=44059888

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10831896A NO2501406T3 (de) 2009-11-19 2010-11-16

Country Status (20)

Country Link
US (2) US8846342B2 (de)
EP (1) EP2501406B8 (de)
JP (2) JP5968784B2 (de)
KR (1) KR101855380B1 (de)
CN (1) CN102724997B (de)
AU (1) AU2010322454B2 (de)
CA (1) CA2780487C (de)
CY (1) CY1119995T1 (de)
DK (1) DK2501406T3 (de)
ES (1) ES2660227T3 (de)
HR (1) HRP20180338T1 (de)
HU (1) HUE038456T2 (de)
IL (1) IL219733A (de)
LT (1) LT2501406T (de)
NO (1) NO2501406T3 (de)
PL (1) PL2501406T3 (de)
PT (1) PT2501406T (de)
SI (1) SI2501406T1 (de)
TR (1) TR201803015T4 (de)
WO (1) WO2011062615A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477794C (en) * 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
CN102724997B (zh) * 2009-11-19 2016-09-21 格林考瓦因有限公司 在原核细胞中产生免疫原性多糖的生物合成系统
AU2012297533B2 (en) * 2011-08-12 2016-02-25 Instituto De Investigaciones Biotecnologicas-Instituto Tecnologico De Chascomus Consejo De Investigaciones Cientificas Y Tecnicas, Universidad Nacional De San Martin Method of diagnosing bacterial infections using bacterial glycoproteins
CA2879272A1 (en) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides and uses thereof
US20150353940A1 (en) * 2013-08-05 2015-12-10 Absci, Llc Vectors for use in an inducible coexpression system
EP2724730A1 (de) * 2012-10-29 2014-04-30 Institut Pasteur Glycokonjugate und deren Verwendung als potentielle Impfstoffe gegen Infektion durch Shigella flexneri
JP6553517B2 (ja) 2013-01-17 2019-07-31 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Mdr大腸菌特異的抗体
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
EA201690529A1 (ru) 2013-10-11 2016-11-30 Гликоваксин Аг Способы модификации клетки-хозяина
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
JP6682451B2 (ja) * 2014-04-17 2020-04-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変型宿主細胞およびその使用
KR101629656B1 (ko) * 2014-10-24 2016-06-14 충남대학교산학협력단 면역증강효과를 갖는 수용성 다당체 및 이를 함유하는 조성물
DK3240895T3 (da) * 2014-12-30 2022-04-11 Glaxosmithkline Biologicals Sa Sammensætninger og fremgangsmåder til proteinglykosylering
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CA3006400A1 (en) 2015-11-30 2017-06-08 Limmatech Biologics Ag Methods of producing glycosylated proteins
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
KR102574882B1 (ko) 2019-03-18 2023-09-04 얀센 파마슈티칼즈, 인코포레이티드 대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법
SG11202110301TA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EP3770269A1 (de) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantifizierung von biokonjugatglykosylierung
BR112022024294A2 (pt) 2020-06-18 2023-02-28 Glaxosmithkline Biologicals Sa Bioconjugado shigella-tetravalente (shigella4v)".
US20230226175A1 (en) 2020-06-25 2023-07-20 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
CN112877246B (zh) * 2021-02-23 2022-01-18 山东省滨州畜牧兽医研究院 一种高效制备霍乱弧菌菌影的方法
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142915A (ja) * 1983-12-28 1985-07-29 Lion Corp 口腔用組成物
ATE67786T1 (de) 1984-08-01 1991-10-15 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
US5242809A (en) * 1986-02-28 1993-09-07 Smithkline Beecham Corporation Gal operon of streptomyces
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
US5665559A (en) * 1989-05-18 1997-09-09 The United States Of America As Represented By The Secretary Of The Navy Production of monoclonal antibodies to bacteroides gingivalis by hybridoma BGII, VF9/2D
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US6365723B1 (en) * 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
JP2003524395A (ja) 1999-03-02 2003-08-19 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 細胞内シアリル化経路の操作
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
EP1294910B1 (de) 2000-06-30 2008-11-19 VIB vzw Modifikation der proteinglycosylierung in pichia pastoris
EP1357182A1 (de) * 2000-12-21 2003-10-29 Kyowa Hakko Kogyo Co., Ltd Verfahren zur herstellung von udp-n-acetylgalactosamin und n-acetylgalactosamin-haltigem saccharid
US20020150968A1 (en) * 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
US20020132320A1 (en) * 2001-01-10 2002-09-19 Wang Peng George Glycoconjugate synthesis using a pathway-engineered organism
US6696814B2 (en) 2001-07-09 2004-02-24 Tyco Electronics Corporation Microprocessor for controlling the speed and frequency of a motor shaft in a power tool
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7541043B2 (en) * 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
KR20130101592A (ko) 2002-03-07 2013-09-13 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
CA2494223C (en) 2002-08-01 2012-10-02 National Research Council Of Canada Campylobacter glycans and glycopeptides
EP2657251B1 (de) 2004-05-24 2018-03-21 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Lebender, oraler Impfstoff gegen Shigella dysenteriae Serotyp 1
WO2006102652A2 (en) * 2005-03-24 2006-09-28 Neose Technologies, Inc. Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
SI2311972T1 (sl) * 2005-05-11 2015-08-31 Eth Zuerich Rekombinantni N-glikozilirani proteini iz prokariontskih celic
US20070202578A1 (en) * 2005-08-26 2007-08-30 Centre National De La Recherche Scientifique (Cnrs) Production of globosides oligosaccharides using metabolically engineered microorganisms
EP2240595B2 (de) * 2008-01-03 2019-07-24 Cornell Research Foundation, Inc. Expression eines glycosylierten proteins in prokaryonten
US20100286067A1 (en) * 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
HUE039413T2 (hu) * 2008-02-20 2018-12-28 Glaxosmithkline Biologicals Sa Prokarióta sejtekbõl származó rekombináns N-glikozilált fehérjékbõl készített biokonjugátumok
CA2757224C (en) * 2009-03-27 2016-12-06 Eidgenoessische Technische Hochschule Zuerich Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
CN102724997B (zh) * 2009-11-19 2016-09-21 格林考瓦因有限公司 在原核细胞中产生免疫原性多糖的生物合成系统
US9221898B2 (en) * 2010-02-11 2015-12-29 The Governors Of The University Of Alberta N-linked glycan compounds
EP2566507B1 (de) * 2010-05-06 2017-11-22 GlaxoSmithKline Biologicals SA Konjugatimpstoffe mit kapselförmigen gram-positiven bakterien
ES2684087T3 (es) * 2010-09-03 2018-10-01 The Governors Of The University Of Alberta Péptido que contiene múltiples sequones de glicosilación ligada a N
US8846373B2 (en) * 2011-07-29 2014-09-30 The University Of Wyoming Methods of using a bacterial GlcNAc-6-P 2′- epimerase to promote sialylation of glycoconjugates
AU2012306345A1 (en) * 2011-09-06 2014-03-20 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
CA3125293A1 (en) * 2012-11-07 2014-05-15 Glaxosmithkline Biologicals Sa Production of recombinant vaccine in e. coli by enzymatic conjugation
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine

Also Published As

Publication number Publication date
CA2780487C (en) 2019-05-21
TR201803015T4 (tr) 2018-03-21
CA2780487A1 (en) 2011-05-26
PT2501406T (pt) 2018-02-21
EP2501406A1 (de) 2012-09-26
CN102724997B (zh) 2016-09-21
DK2501406T3 (en) 2018-02-26
US8846342B2 (en) 2014-09-30
JP2017018098A (ja) 2017-01-26
IL219733A0 (en) 2012-07-31
AU2010322454A1 (en) 2012-06-07
JP5968784B2 (ja) 2016-08-10
PL2501406T3 (pl) 2018-05-30
KR20120102086A (ko) 2012-09-17
EP2501406A4 (de) 2013-04-24
HUE038456T2 (hu) 2018-10-29
SI2501406T1 (en) 2018-03-30
US20130028926A1 (en) 2013-01-31
CN102724997A (zh) 2012-10-10
KR101855380B1 (ko) 2018-05-08
US9764018B2 (en) 2017-09-19
LT2501406T (lt) 2018-03-26
HRP20180338T1 (hr) 2018-04-06
WO2011062615A1 (en) 2011-05-26
EP2501406B8 (de) 2018-01-24
ES2660227T3 (es) 2018-03-21
JP2013511520A (ja) 2013-04-04
EP2501406B1 (de) 2017-12-20
AU2010322454B2 (en) 2016-05-19
IL219733A (en) 2017-08-31
US20150190492A1 (en) 2015-07-09
CY1119995T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
BR112012012396A2 (de)
BR112012008267A2 (de)
BR112012003062A2 (de)
BR112012008195A2 (de)
BR112012000607A2 (de)
BRPI0925311A2 (de)
BRPI0924307A2 (de)
BR112012003080A2 (de)
BR122021004633A2 (de)
BR122017024704A2 (de)
BR112012012487A2 (de)
BR112012000665A2 (de)
BR112012003853A2 (de)
BR112012012080A2 (de)
BR112012009797A2 (de)
BR112012009446A2 (de)
BR112012009703A2 (de)
BR112012010357A2 (de)
BR112012007656A2 (de)
BR122019005883A2 (de)
BR112012002627A2 (de)
BR112012001263A2 (de)
BR112012000159A2 (de)
BR112012014856A2 (de)
BRPI0924534A2 (de)